{
    "nct_id": "NCT05848011",
    "official_title": "A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer",
    "inclusion_criteria": "* Metastatic castration-resistant adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features.\n* Participants must have â‰¥ 1 metastatic (measurable or non-measurable per PCWG3) lesion.\n* Participant has prostate cancer progression at study entry based on PCWG3 criteria.\n* Participant shows evidence of disease progression after receiving at least 1 prior androgen receptor axis-targeted therapy (ARAT) regimen (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide).\n* Patients with known history of documented breast cancer gene (BRCA) mutation (germline or somatic) must have received an approved poly ADP ribose polymerase (PARP) inhibitor regimen.\n* Participants must have adequate performance status, life expectancy and laboratory values.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any condition preventing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.\n* Received prior chemotherapy for mCRPC or checkpoint inhibitors for prostate cancer.\n* Current active or chronic infections.\n* Any clinically significant heart, lung, or gastrointestinal disorders.\n* Allergy to any of the study treatments or components of the study treatments.",
    "miscellaneous_criteria": ""
}